Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M

Autolus Therapeutics plc

Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.
FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.
UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.
Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.